Criterium Inc.

Full-service, dedicated, and data-driven CRO providing innovative clinical trial solutions from thought to finish.

[Criterium Inc. @CriteriumInc]

D. Ross Camidge, MD, PhD @DRCamidge @CUCancer & Senior Advisor of Criterium's Thoracic Oncology Investigators Consortium discusses his impressive career advancing solutions for lung cancer and his journey as a patient.
https://t.co/METdoYFL8L

[CU Anschutz Cancer Center @CUCancerCenter]

The U.S. News & World Report has released its 2026-2027 Best Global Universities rankings. We're proud of our oncologists for their tireless efforts in the fight against cancer. This ranking of @CUAnschutz reflects their work: https://t.co/tgzw9y568r

[Criterium Inc. @CriteriumInc]

The optimal duration of 1st-line trastuzumab treatment for de novo stage IV HER2-positive MBC patients after complete response (CR) is not known. New research from our Academic Breast Cancer Consortium (ABRCC) aims to find out.
https://t.co/K9Y8zPMb0C
#BreastCancerResearch

[Criterium Inc. @CriteriumInc]

Read our new case report from the Academic Breast Cancer Consortium (ABRCC) describing a patient with metastatic estrogen receptor–positive, HER2-nonamplified breast cancer. https://t.co/kJuajYzscM
#BreastCancer

[Criterium Inc. @CriteriumInc]

.@TomFlaigMD from @CUAnschutz and Director of Criterium's Academic Urology Research Investigators Consortium (AURIC) discussed new treatment guidelines at the National Comprehensive Cancer Network annual conference. https://t.co/ugIVEVwxgV
#UrologyResearch

[Criterium Inc. @CriteriumInc]

Investigator-initiated trials may address important biological and clinical questions that may not be prioritized by pharmaceutical sponsors. We performed a retrospective study of IIT concepts submitted through the Academic Thoracic Oncology Consortium: https://t.co/5Q4E4Ai1vi

[Criterium Inc. @CriteriumInc]

Are you researching a condition specific to men? Criterium has extensive experience in designing trials for Erectile Dysfunction, Hormone Replacement Therapy, Benign Prostatic Hypertrophy (BPH), and other areas of men's health. Learn more: https://t.co/7Pm1QAs1OH

[Criterium Inc. @CriteriumInc]

A Phase 3 clinical trial led by @neerajaiims @HuntsmanCancer & Criterium's Academic Urology Research Investigators Consortium (AURIC), found that a combination #prostatecancer treatment could curb disease progression in some patients.
https://t.co/sjOl8jsw4l

[Criterium Inc. @CriteriumInc]

An experimental drug by Revolution Medicines showed positive results in a Phase 3 trial. Dr. Paul Oberstein, a #pancreaticcancer expert and member of Criterium's Academic GI Cancer Consortium (AGICC), discusses the impact of the study and new data.

https://t.co/0UESjZZaPP

[Criterium Inc. @CriteriumInc]

June is #MensHealthMonth, and with the mortality rate higher for men in 8 out of 10 leading causes of death, including cancer and diabetes, raising awareness of early detection is important. Learn about promising research: https://t.co/lhwACkUfeO

[Criterium Inc. @CriteriumInc]

Charles C. Hsu, M.D., Ph.D. from @UAZCancerand Criterium's Academic Thoracic Oncology Medical Investigators Consortium co-authored a paper exploring stereotactic body radiation therapy (SBRT) over conventional radiation therapy for spine bone metastases. https://t.co/dQwOrgjhxw

[Criterium Inc. @CriteriumInc]

In our latest newsletter, get updates in oncology research from our consortia members and learn about advancements in rare disease research: https://t.co/P0HWVBJ5R2

#OncologyResearch #ClinicalResearch #CRO

[Criterium Inc. @CriteriumInc]

A new publication explores de‑escalating therapy for breast cancer patients with low risk of reoccurrence. Learn more: https://t.co/GXEkGqtK7o

#BreastCancer #Oncology #CRO

[Criterium Inc. @CriteriumInc]

Reva K. Basho, MD from @EMILosAngeles and Criterium's Academic Breast Cancer Consortium (ABRCC) discusses the role of AI in breast cancer diagnosis and treatment.
https://t.co/rxbxbBXD4q
#BreastCancer

[Criterium Inc. @CriteriumInc]

Though rare diseases affect almost 30 million Americans, research challenges and hurdles for therapeutic development persist.

Several research advancements have opened up possibilities for new therapies, bringing hope to patients and families.
https://t.co/9SagmQNMDX

[Criterium Inc. @CriteriumInc]

Anup Kasi, MD, MPH @KUMedCenter & Criterium's GI Cancer Consortium presented results of a study exploring novel KRAS-targeted treatments, demonstrating promising efficacy in early-phase studies for pancreatic ductal adenocarcinoma. @anup_kasi
https://t.co/egUd4YJ1cr

[Criterium Inc. @CriteriumInc]

Because rare diseases can impact a small number of individuals, companies may be less likely to invest in treatments. Criterium has experience in clinical trial services for Orphan Indication research, such as colorectal cancer mutation. https://t.co/7Pm1QAs1OH

[Criterium Inc. @CriteriumInc]

Criterium brings a high level of expertise, and high-value technology to every clinical trial.
https://t.co/FRzonGjSCg

#clinicaltrialsday

[Criterium Inc. @CriteriumInc]

3 patients have been treated with RYZ401, a radiopharmaceutical therapy for neuroendocrine tumors. Heloisa Soares, MD, PhD @huntsmancancer & Criterium's GI Cancer Consortium is leading the Phase 1 trial. @helops79
https://t.co/5w4GClXR5k

[Criterium Inc. @CriteriumInc]

Looking for a CRO for you allergy and asthma trial? From Seasonal Allergic Rhinitis to mild, moderate, and severe Asthma, Criterium has extensive experience in this therapeutic area. Let's discuss your next trial: https://t.co/Ge9dTgZXMf
#ClinicalResearch #CRO